全文获取类型
收费全文 | 1176篇 |
免费 | 56篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 55篇 |
妇产科学 | 15篇 |
基础医学 | 143篇 |
口腔科学 | 20篇 |
临床医学 | 108篇 |
内科学 | 276篇 |
皮肤病学 | 27篇 |
神经病学 | 91篇 |
特种医学 | 62篇 |
外科学 | 200篇 |
综合类 | 10篇 |
预防医学 | 78篇 |
眼科学 | 10篇 |
药学 | 84篇 |
中国医学 | 1篇 |
肿瘤学 | 47篇 |
出版年
2023年 | 8篇 |
2022年 | 16篇 |
2021年 | 25篇 |
2020年 | 15篇 |
2019年 | 25篇 |
2018年 | 36篇 |
2017年 | 24篇 |
2016年 | 32篇 |
2015年 | 23篇 |
2014年 | 29篇 |
2013年 | 32篇 |
2012年 | 80篇 |
2011年 | 65篇 |
2010年 | 43篇 |
2009年 | 39篇 |
2008年 | 36篇 |
2007年 | 43篇 |
2006年 | 42篇 |
2005年 | 29篇 |
2004年 | 32篇 |
2003年 | 41篇 |
2002年 | 53篇 |
2001年 | 33篇 |
2000年 | 45篇 |
1999年 | 39篇 |
1998年 | 23篇 |
1997年 | 21篇 |
1996年 | 18篇 |
1995年 | 19篇 |
1994年 | 16篇 |
1993年 | 19篇 |
1992年 | 21篇 |
1991年 | 21篇 |
1990年 | 18篇 |
1989年 | 26篇 |
1988年 | 22篇 |
1987年 | 17篇 |
1986年 | 12篇 |
1985年 | 19篇 |
1984年 | 4篇 |
1983年 | 3篇 |
1982年 | 10篇 |
1981年 | 7篇 |
1980年 | 9篇 |
1979年 | 5篇 |
1978年 | 7篇 |
1977年 | 6篇 |
1976年 | 7篇 |
1975年 | 7篇 |
1974年 | 3篇 |
排序方式: 共有1235条查询结果,搜索用时 15 毫秒
41.
Monmeneu Menadas JV Marín Ortuño F Reyes Gomis F Jordán Torrent A García Martínez M Bodí Peris V García de Burgos de Rico E 《The Journal of heart valve disease》2002,11(2):199-203
BACKGROUND AND AIM OF THE STUDY: The study aim was to determine whether beta-blocker treatment (atenolol) improves cardiopulmonary exercise performance and ventilatory response in patients with mitral stenosis in sinus rhythm. METHODS: A prospective study comparing the results of cardiopulmonary exercise tests (CPETs) was performed before and after atenolol therapy in 17 patients in NYHA classes I and II with mitral stenosis in sinus rhythm. Transthoracic echocardiography was performed pre-study, and left ventricular diameters, ejection fraction and mitral valve area monitored. CPETs (Naughton protocol) were performed by two different investigators before and after one-week atenolol therapy (50 mg/day). The second investigator was blinded to the result of the baseline test. O2 consumption, CO2 production, ventilatory parameters and respiratory exchange ratios were measured on line. RESULTS: Maximal O2 uptake (VO2max) did not differ significantly before and after beta-blockade (median 16.8 and 15.0 ml/kg/min, respectively. Median heart rate at rest (72 versus 55 beats/min; p = 0.0003) and during peak exercise (153 versus 105 beats/min; p = 0.0003), and anaerobic threshold (10 versus 8.9 ml/kg/min; p = 0.02) were lower with beta-blockade compared with the baseline state. Minute ventilation at maximum exercise (41 versus 40 l/min) and ventilatory equivalent for CO2 (34 versus 35) were unchanged with atenolol therapy, indicating no improvement in ventilatory performance. When patients were grouped into those in whom VO2max was improved with atenolol therapy (n = 7) and those in whom it was impaired (n = 10), there were no inter-group differences with respect to age, left ventricular function, severity of mitral stenosis, NYHA class and grade of beta-blockade reached. Four patients felt symptomatically worse during atenolol treatment (lower NYHA functional class). CONCLUSION: Beta-blockade does not improve exercise tolerance in patients with mitral stenosis in sinus rhythm. In addition, ventilatory performance does not change with treatment. 相似文献
42.
Puchades MJ González Rico MA Pons S Miguel A Bonilla B 《Nefrología : publicación oficial de la Sociedad Espa?ola Nefrologia》2004,24(Z3):72-75
We present a case of Gitelman's Syndrome in a 20 year-old woman who came to our service with weakness, asthenia, leg cramps and tetany. Laboratory studies revealed metabolic alkalosis with hypokalemia, hypomagnesemia and low calcium in a 24-hour urine test. The diagnosis of this syndrome is made in some cases during adult life because this syndrome is asymptomatic over several years. Gitelman's Syndrome is autosomal recessive as is Bartter's Syndrome. The gene is located in chromosome 16q, which encodes the cotransporter Na/Cl sensitive to thiazide in the distal convoluted tubule. The defect of cotransporter produces an alteration of sodium reabsorption that causes electrolytic disorders typical of this Syndrome and different from Bartter's Syndrome. The typical electrolytic alterations are hypocalciuria and hypomagnesemia secondary to high urinary magnesium excretion. The prognosis of this syndrome is excellent and treatment consists in correction of serum electrolytes with oral administration of magnesium and potassium. In spite of this treatment, in some cases it is very difficult to reach normal serum levels of magnesium because of the high doses of oral magnesium, which produce common crises of diarrhea that increase magnesium gastrointestinal losses. 相似文献
43.
Summary In an open study, we have assessed the bone/soft tissue uptake index in recent osteoporotic vertebral collapse using scintigraphy. The evolution of these cases was followed-up at 6 months in 22 patients treated with 100 IU of salmon calcitonin plus 500 mg of elemental calcium/10 days per month and in 18 patients treated with 500 mg of elemental calcium only on a daily basis. There were no index differences between groups prior to treatment. At six months, the group treated with calcitonin plus calcium showed a significant decrease from 10.2±6.4 to 3.2±1.1 (p<0.001), while the calcium only group did not show any significant changes (12.1±6.6 vs 9.2±4.6), considering that there were significant differences between groups (p<0.001). On a mid-term basis, these results have shown the values of the bone soft tissue index in the follow-up of osteoporotic vertebral collapse. 相似文献
44.
Detecting SARS‐CoV‐2 RNA in conjunctival secretions: Is it a valuable diagnostic method of COVID‐19?
45.
Transneuronal tracing of diverse CNS circuits by Cre-mediated induction of wheat germ agglutinin in transgenic mice
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Braz JM Rico B Basbaum AI 《Proceedings of the National Academy of Sciences of the United States of America》2002,99(23):15148-15153
Systems neuroscience addresses the complex circuits made by populations of neurons in the CNS and the cooperative function of these neurons. Improved approaches to the neuroanatomical analysis of CNS circuits are thus of great interest. In fact, significant advances in tract-tracing methods have recently been made by using transgenic mice that express transneuronal lectin tracers under the control of neuron-specific promoters. The utility of those animals, however, is limited to the CNS circuit influenced by the particular promoter. Here, we describe a new transgenic mouse that can be used for transneuronal tracing analysis of circuits in any region of the brain or spinal cord. The transgene in these mice results in expression of LacZ in neurons throughout the CNS. Excision of the LacZ gene by Cre-mediated recombination initiates expression of the lectin, wheat germ agglutinin (WGA). To illustrate the diverse uses of these ZW (LacZ-WGA) mice, we triggered WGA expression either by crossing the mice with two Cre-expressing transgenic mouse lines or by microinjecting a Cre-expressing adeno-associated virus into the cerebellum or cerebral cortex. Both approaches resulted in extensive WGA expression in the cell bodies and dendrites of neurons in which the recombination event occurred, as well as anterograde and transneuronal transport of the lectin to second and third order neurons. Because the lectin can be induced in developing and adult animals, and in all regions of the brain and spinal cord, these ZW may prove extremely valuable for numerous studies of CNS circuit analysis. 相似文献
46.
47.
Bochud PY Bibert S Kutalik Z Patin E Guergnon J Nalpas B Goossens N Kuske L Müllhaupt B Gerlach T Heim MH Moradpour D Cerny A Malinverni R Regenass S Dollenmaier G Hirsch H Martinetti G Gorgiewski M Bourlière M Poynard T Theodorou I Abel L Pol S Dufour JF Negro F;Swiss Hepatitis C Cohort Study Group;ANRS HC EP Genoscan Study Group 《Hepatology (Baltimore, Md.)》2012,55(2):384-394
Genetic polymorphisms near IL28B are associated with spontaneous and treatment-induced clearance of hepatitis C virus (HCV), two processes that require the appropriate activation of the host immune responses. Intrahepatic inflammation is believed to mirror such activation, but its relationship with IL28B polymorphisms has yet to be fully appreciated. We analyzed the association of IL28B polymorphisms with histological and follow-up features in 2335 chronically HCV-infected Caucasian patients. Assessable phenotypes before any antiviral treatment included necroinflammatory activity (n = 1,098), fibrosis (n = 1,527), fibrosis progression rate (n = 1,312), and hepatocellular carcinoma development (n = 1,915). Associations of alleles with the phenotypes were evaluated by univariate analysis and multivariate logistic regression, accounting for all relevant covariates. The rare G allele at IL28B marker rs8099917-previously shown to be at risk of treatment failure-was associated with lower activity (P = 0.04), lower fibrosis (P = 0.02) with a trend toward lower fibrosis progression rate (P = 0.06). When stratified according to HCV genotype, most significant associations were observed in patients infected with non-1 genotypes (P = 0.003 for activity, P = 0.001 for fibrosis, and P = 0.02 for fibrosis progression rate), where the odds ratio of having necroinflammation or rapid fibrosis progression for patients with IL28B genotypes TG or GG versus TT were 0.48 (95% confidence intervals 0.30-0.78) and 0.56 (0.35-0.92), respectively. IL28B polymorphisms were not predictive of the development of hepatocellular carcinoma. CONCLUSION: In chronic hepatitis C, IL28B variants associated with poor response to interferon therapy may predict slower fibrosis progression, especially in patients infected with non-1 HCV genotypes. 相似文献
48.
Boursier J de Ledinghen V Zarski JP Fouchard-Hubert I Gallois Y Oberti F Calès P;multicentric groups from SNIFF VINDIAG ANRS/HC/EP FIBROSTAR studies 《Hepatology (Baltimore, Md.)》2012,55(1):58-67
The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 ("successive algorithms"). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10(-3) ) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10(-3) ). Similarly, successive BA had significantly (P ≤ 10(-3) ) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10(-3) ). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy. CONCLUSION: SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis. 相似文献
49.
Biopsy‐proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal
下载免费PDF全文
![点击此处可从《Transplant international》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Manuel Rodríguez‐Perálvarez Jose M. Rico‐Juri Emmanuel Tsochatzis Patrizia Burra Manuel De la Mata Jan Lerut 《Transplant international》2016,29(9):961-973
Biopsy‐proven acute cellular rejection (ACR) is the primary efficacy endpoint in most randomized trials evaluating immunosuppression in liver transplantation. However, ACR is not a major cause of graft loss, and a certain grade of immune activation may be even beneficial for long‐term graft acceptance. Validated criteria to select candidates for liver biopsy are lacking, and routine clinical practice relies on liver tests, which are inaccurate markers of ACR. Indeed, both the agreement among clinicians to select candidates for liver biopsy and the correlation between the clinical suspicion of ACR and histological findings are poor. In randomized trials evaluating immunosuppression protocols, this concern grows exponentially due to the open‐label and multicenter nature of most studies. Therefore, biopsy‐proven ACR is a suboptimal efficacy endpoint given its limited impact on prognosis and the heterogeneous diagnosis, which may increase the risk of bias. Chronic rejection and/or graft loss would be more appropriate endpoints, but would certainly require larger studies with prolonged surveillances. An objective method to select candidates for liver biopsy is therefore urgently needed, and only severe episodes of histological ACR should be considered as potentially harmful. Emerging surrogate markers of ACR and antibody‐mediated rejection require further investigation to determine their clinical role. 相似文献
50.
Risk Factors Associated With Early Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: Results From a Multinational Matched Case–Control Study
下载免费PDF全文
![点击此处可从《American journal of transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
F. Lpez‐Medrano J. T. Silva M. Fernndez‐Ruiz P. L. Carver C. van Delden E. Merino M. J. Prez‐Saez M. Montero J. Coussement M. de Abreu Mazzolin C. Cervera L. Santos N. Sab A. Scemla E. Cordero L. Cruzado‐Vega P. L. Martín‐Moreno
. Len E. Rudas A. Ponce de Len M. Arriola R. Lauzurica M. David C. Gonzlez‐Rico F. Henríquez‐Palop J. Fortún M. Nucci O. Manuel J. R. Pao‐Pardo M. Montejo P. Muoz B. Snchez‐Sobrino A. Mazuecos J. Pascual J. P. Horcajada T. Lecompte C. Lumbreras A. Moreno J. Carratal M. Blanes D. Hernndez E. A. Hernndez‐Mndez M. C. Farias M. Perell‐Carrascosa J. M. Morales A. Andrs J. M. Aguado 《American journal of transplantation》2016,16(7):2148-2157
Risk factors for invasive pulmonary aspergillosis (IPA) after kidney transplantation have been poorly explored. We performed a multinational case–control study that included 51 kidney transplant (KT) recipients diagnosed with early (first 180 posttransplant days) IPA at 19 institutions between 2000 and 2013. Control recipients were matched (1:1 ratio) by center and date of transplantation. Overall mortality among cases was 60.8%, and 25.0% of living recipients experienced graft loss. Pretransplant diagnosis of chronic pulmonary obstructive disease (COPD; odds ratio [OR]: 9.96; 95% confidence interval [CI]: 1.09–90.58; p = 0.041) and delayed graft function (OR: 3.40; 95% CI: 1.08–10.73; p = 0.037) were identified as independent risk factors for IPA among those variables already available in the immediate peritransplant period. The development of bloodstream infection (OR: 18.76; 95% CI: 1.04–339.37; p = 0.047) and acute graft rejection (OR: 40.73, 95% CI: 3.63–456.98; p = 0.003) within the 3 mo prior to the diagnosis of IPA acted as risk factors during the subsequent period. In conclusion, pretransplant COPD, impaired graft function and the occurrence of serious posttransplant infections may be useful to identify KT recipients at the highest risk of early IPA. Future studies should explore the potential benefit of antimold prophylaxis in this group. 相似文献